About Pykus Therapeutics
Pykus Therapeutics is a company based in Boston (United States) founded in 2016.. Pykus Therapeutics has raised $2.49 million across 2 funding rounds from investors including MassChallenge. Pykus Therapeutics offers products and services including PYK-2101. Pykus Therapeutics operates in a competitive market with competitors including Kodiak Sciences, Second Sight, Pixium Vision, iScience Interventional and Medical Instrument Development Laboratories, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Pykus Therapeutics Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.49 M (USD)
in 2 rounds
-
Latest Funding Round
$2.49 M (USD), Seed
Feb 04, 2021
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pykus Therapeutics
Pykus Therapeutics offers a comprehensive portfolio of products and services, including PYK-2101. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Biodegradable hydrogel for retinal healing without recovery burdens
Unlock access to complete
Unlock access to complete
Funding Insights of Pykus Therapeutics
Pykus Therapeutics has successfully raised a total of $2.49M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.49 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Seed — $2.5M
-
First Round
First Round
(03 Nov 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Seed - Pykus Therapeutics | Valuation |
investors |
|
| Nov, 2017 | Amount | Grant - Pykus Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pykus Therapeutics
Pykus Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MassChallenge. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage entrepreneurs are accelerated through MassChallenge's program.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pykus Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Pykus Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pykus Therapeutics Comparisons
Competitors of Pykus Therapeutics
Pykus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kodiak Sciences, Second Sight, Pixium Vision, iScience Interventional and Medical Instrument Development Laboratories, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Implantable visual prosthetics for blind individuals are developed and provided.
|
|
| domain | founded_year | HQ Location |
Bionic vision restoration systems are provided for sight restoration.
|
|
| domain | founded_year | HQ Location |
Microcatheter and imaging technologies for ophthalmic procedures are developed.
|
|
| domain | founded_year | HQ Location |
Develops ophthalmic products for ophthalmic system manufacturers
|
|
| domain | founded_year | HQ Location |
Delivers tailored solutions for treating age-related macular degeneration.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pykus Therapeutics
Frequently Asked Questions about Pykus Therapeutics
When was Pykus Therapeutics founded?
Pykus Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Pykus Therapeutics located?
Pykus Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Pykus Therapeutics a funded company?
Pykus Therapeutics is a funded company, having raised a total of $2.49M across 2 funding rounds to date. The company's 1st funding round was a Grant of $100K, raised on Nov 03, 2017.
What does Pykus Therapeutics do?
Retinal disorders are a common cause of debilitating vision loss and often the only treatment is surgery. Each year, more than 350 000 such surgeries are performed in the US alone. Often, a gas bubble must be placed in the eye to help the retina heal in place after surgery. So that this gas bubble is directed against the retina, patients have to position face-down for one week or more. And while the gas is in the eye (up to 4-8 weeks), patients have very limited vision and cannot fly. Pykus Therapeutics is developing a novel polymer that will provide better retinal tamponade (and therefore better patient outcomes) while eliminating the suffering and lifestyle limitations currently placed on patients after surgery. The polymer is in late-stage pre-clinical development. It provides a 360-degree tamponade force, which eliminates the need for post-operative patient positioning. It is also optically clear with an index of refraction nearing that of the native vitreous gel, which allows patients with a healthy macula to see clearly post-operatively. Finally, it is biodegradable which avoids the need for a second trip to the operating room for removal.
Who are the top competitors of Pykus Therapeutics?
Pykus Therapeutics's top competitors include Kodiak Sciences, Second Sight and Pixium Vision.
What products or services does Pykus Therapeutics offer?
Pykus Therapeutics offers PYK-2101.
Who are Pykus Therapeutics's investors?
Pykus Therapeutics has 1 investor. Key investors include MassChallenge.